Semaglutide is associated with lower risk of cardiovascular events compared with tirzepatide in patients with overweight or obesity and ASCVD and without diabetes in routine clinical practice
Sorry! It looks like the page you are trying to access contains materials that are still under embargo. Please come back and check again later.